Botulinum Toxin Type A
DrugBotulinum Toxin Type A
NCT Number: NCT01390922
The objective of this post-marketing surveillance study is to collect safety, efficacy and usage data on botulinum injection in subjects with upper or lower limb spasticity on the long-term use in clinical practice and to identify the factors affecting the safety or efficacy.
Looking for future studies?
Notify MeAll sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Botulinum Toxin Type A
Time frame: 1 year
Time frame: 1 year
Time frame: 1 year
Time frame: 1 year
Time frame: 1 year
GlaxoSmithKline
Industry
Special Drug Use Investigation for Botox® (Botulinum) Spasticity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02325310
Infections, Measles
Paris, France
View Trial DetailsNCT06331702
Arbovirus Infections, Brain Diseases
Nanjing, Jiangsu, China
View Trial DetailsNCT01712906
Infections, Mononegavirales Infections
Shijiazhuang, Hebei, China
View Trial DetailsNCT05145166
Infections, Mononegavirales Infections
Baoji, Shanxi, China
View Trial Details